More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

What was the most noteworthy activity from CDMOs/CMOs in 2019? DCAT Value Chain Insights’ Top 10 ranking reveals the companies involved in the most significant mergers and acquisitions and expansions from 2019. CDMOs/CMOs: A Top 10 Ranking of...

Bristol-Myers Squibb completed its $74-billion acquisition of Celgene last month to form a newly combined company with eight products of over $1 billion in annual sales and near-term revenue potential of over $15 billion in new launches. What was...

As 2019 comes to a close, what were the top news stories shaping the pharmaceutical industry? From mega acquisitions to deal-making in cell and gene therapies, to shifting supply lines from a still-to-be resolved Brexit and ongoing trade talks in...

The US is the single largest pharmaceutical market in the world, but it lags behind other countries in API production for drugs marketed in the US. How are the supply lines for APIs evolving for US-marketed drugs? API supply lines for US...

Biosimilars represent a small part of the global pharmaceutical market with Europe leading in biosimilar approvals comparative to the US. What are the challenges and opportunities for biosimilar uptake and what have been developments thus far in...

Earlier this month, FDA released results from its ongoing investigations of nitrosamine impurities in certain APIs, most recently ranitidine, and earlier “sartan”-containing APIs. What did the FDA find, and does it impact regulatory testing...

Parenteral drugs are an important part of the pharmaceutical market due to the increase in biologics and complex active pharmaceutical ingredients (APIs) in development. DCAT Value Chain Insights examines key product, manufacturing, and...

What are the key issues facing procurement and supply-chain leaders? From digital transformations to talent development to risk mitigation, DCAT Value Chain Insights provides perspective from thought leaders. Providing perspective is Robert...

With a $3-billion strategic alliance with Sumitomo Dainippon Pharma in the offing, Vivek Ramaswamy, CEO and founder of Roivant Sciences, is looking to take its “hub and spoke” business model for drug development to the next level. Inside Roivant...